Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Observational Program to Assess Routine Use of Add-back Therapy in Patients With Endometriosis in Russian Federation, Planned for 6-month Course of Lucrin Depot® (Leuprorelin)

This study has been completed.
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) ) Identifier:
First received: February 10, 2011
Last updated: May 10, 2013
Last verified: May 2013
The purpose of this study is to assess rates of administration of add-back therapy in patients with endometriosis in the Russian Federation, during a 6-month course of gonadoliberin agonist leuprorelin 3.75 mg.

Genital Endometriosis

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Prospective, Multi-Center, Observational Program to Assess Routine Use of Add-back Therapy in Patients With Endometriosis in Russian Federation, Planned for 6-month Course of Gonadoliberin Agonist Lucrin Depot.

Resource links provided by NLM:

Further study details as provided by AbbVie:

Primary Outcome Measures:
  • Percentage of Participants Administered Add-back Therapy During a 6-month Course of Leuprorelin Treatment [ Time Frame: 6 months ]
    The percentage of participants who received hormone add-back therapy or non-hormone add-back therapy to reduce estrogen deficiency symptom, following local guidelines or therapeutic recommendations, during the 6-month treatment period with leuprorelin.

Secondary Outcome Measures:
  • Percent Compliance to Treatment With Leuprorelin [ Time Frame: 6 months ]
    Compliance to treatment was calculated as the number of leuprorelin doses administered / number of doses prescribed * 100.

  • Participants With Estrogen Deficiency Symptoms [ Time Frame: 6 months ]

    Estrogen deficiency symptoms include:

    • hot flashes,
    • headaches,
    • palpitations at rest,
    • insomnia,
    • fluctuation of mood.

Enrollment: 391
Study Start Date: February 2011
Study Completion Date: May 2012
Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)

Patients with genital endometriosis received leuprorelin (Lucrin Depot®) in accordance with the respective marketing authorization/manufacturer's directions. All participants received leuprorelin for up to 6 months intramuscularly at a dose of 3.75 mg once a month. If intramuscular administration was not possible, leuprorelin was injected subcutaneously at a dose of 3.75 mg once a month. The first injection was to be carried out on the 3rd day of a menstrual period.

Accepted options for add-back therapy included: monophasic combined low-dose products for hormonal replacement therapy; combined oral contraceptives; and, if use of hormones was not possible, phytoestrogens with calcium products.

Detailed Description:

This was a non-interventional, observational program in which Lucrin Depot (leuprorelin acetate) and add-back therapy (hormone and non-hormone) were prescribed in the usual manner in accordance with the terms of the local marketing authorization with regards to dose, population and indication (for leuprorelin acetate) and with regards to the local guidelines or therapeutic recommendation (for add-back therapy).

The rationale for the study was the necessity to characterize the patient population and long-term leuprorelin acetate administration in the Russian Federation. Further, it was important to characterize the compliance, tolerability, and safety profile of this therapy in the routine clinical care setting in the Russian Federation.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Primary care clinic

Inclusion Criteria:

  • Age from 18 to 50 years
  • Written Patient Consent for Use/Disclosure of Data
  • Diagnosis of genital endometriosis confirmed by laparoscopy (external genital endometriosis) or ultrasound (internal genital endometriosis)
  • Candidate for treatment with Lucrin Depot for 6-month course
  • Patients with suspected endometriosis suffering from chronic pelvic pain if other reasons for pain are excluded

Exclusion Criteria:

  • Contraindications to administration of Lucrin Depot (leuprorelin):

    • Hypersensitivity to leuprorelin similar products of protein origin or any of the excipients in drug product composition
    • Vaginal bleedings of unknown etiology
    • Hysterectomy
    • Pregnancy and lactation
  • Menopause (absence of cyclic menstrual hemorrhages for 1 year before the start of this program)
  • Acute infectious period, inclusive of acute inflammatory diseases of small pelvic organs
  • Other contraindications that make the patients participation impossible (by investigator judgment)
  • Previous enrollment in the present program
  • Extra-genital endometriosis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01294371

Russian Federation
Site Reference ID/Investigator# 51643
Chelyabinsk, Russian Federation, 454092
Site Reference ID/Investigator# 50563
Ekaterinburg, Russian Federation, 620026
Site Reference ID/Investigator# 50577
Irkutsk, Russian Federation, 664003
Site Reference ID/Investigator# 50561
Izhevsk, Russian Federation, 426039
Site Reference ID/Investigator# 50560
Kazan, Russian Federation, 420043
Site Reference ID/Investigator# 50570
Moscow, Russian Federation, 101000
Site Reference ID/Investigator# 50567
Moscow, Russian Federation, 117036
Site Reference ID/Investigator# 50565
Moscow, Russian Federation, 117997
Site Reference ID/Investigator# 50564
Moscow, Russian Federation, 121552
Site Reference ID/Investigator# 62184
Nizhniy Novgorod, Russian Federation, 603057
Site Reference ID/Investigator# 50558
Nizhny Novgorod, Russian Federation, 603126
Site Reference ID/Investigator# 50557
Orenburg, Russian Federation, 460000
Site Reference ID/Investigator# 50545
Perm, Russian Federation, 614010
Site Reference ID/Investigator# 53156
Perm, Russian Federation, 614066
Site Reference ID/Investigator# 50556
Samara, Russian Federation, 443067
Site Reference ID/Investigator# 50555
Saratov, Russian Federation, 410028
Site Reference ID/Investigator# 50547
St. Petersburg, Russian Federation, 190000
Site Reference ID/Investigator# 50548
St. Petersburg, Russian Federation, 194291
Site Reference ID/Investigator# 50549
St. Petersburg, Russian Federation, 195257
Site Reference ID/Investigator# 50551
St. Petersburg, Russian Federation, 196247
Site Reference ID/Investigator# 50552
St. Petersburg, Russian Federation, 199034
Site Reference ID/Investigator# 50554
Stavropol, Russian Federation, 355002
Site Reference ID/Investigator# 50580
Stavropol, Russian Federation, 355030
Site Reference ID/Investigator# 50579
Tumen, Russian Federation, 625002
Site Reference ID/Investigator# 50575
Vladivostok, Russian Federation, 690600
Site Reference ID/Investigator# 50562
Volzhskiy, Volgograd Region, Russian Federation, 404130
Site Reference ID/Investigator# 48866
Voronezh, Russian Federation, 394000
Site Reference ID/Investigator# 54502
Voronezh, Russian Federation, 394006
Sponsors and Collaborators
AbbVie (prior sponsor, Abbott)
Study Director: Andrey Strugovshchikov, MD AbbVie
  More Information

Additional Information:
Responsible Party: AbbVie (prior sponsor, Abbott) Identifier: NCT01294371     History of Changes
Other Study ID Numbers: P12-762
Study First Received: February 10, 2011
Results First Received: May 10, 2013
Last Updated: May 10, 2013

Keywords provided by AbbVie:
Lucrin Depot
genital endometriosis
6 months therapy

Additional relevant MeSH terms:
Genital Diseases, Female
Fertility Agents, Female
Fertility Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents processed this record on April 24, 2017